白介素-13受體IL-13Ralpha2在治療復發(fā)性惡性膠質瘤中的表達降低（Decreasing expression of the interleukin-13 receptor IL-13Ralpha2 in treated recurrent malignant gliomas）

　　英文摘要：

　　The IL-13Ralpha2 gene encodes for a 65 kDa protein that forms one of the subunits of the interleukin-13 (IL-13) receptor. This gene is highly expressed in various types of human tumors including malignant gliomas. The expression level of IL-13Ralpha2 was examined in a total of 45 tissue samples of anaplastic astrocytomas (AAs) World Health Organization (WHO) grade III, glioblastomas (GBMs) WHO grade IV, and first-recurrent glioblastomas (frGBMs) after treatment with radiation and chemotherapy. IL-13Ralpha2 expression was detected by semiquantitative reverse transcription real-time polymerase chain reaction (PCR) using ABI PRISM 7700 and Qiagen QuantiTect SYBR Green PCR kits. The expression level of IL-13Ralpha2 (15 fold) was significantly reduced in frGBMs compared to the primary GBMs (p = 0.014), and significantly reduced by more than 15 fold (p = 0.003) in all untreated malignant astrocytomas (AAs and GBMs) compared with treated frGBMs. Expression of IL-13Ralpha2 seems to be lower in frGBMs compared to GBMs. The promising antitumor effect of IL-13 cytotoxin could be greatly reduced in frGBM or only achievable with higher amounts of cytotoxin, due to the significantly lower expression of the cytotoxin's target structure.

　　中文摘要：

　　IL-13Ralpha2基因編碼一個65 kDa蛋白，該蛋白形成白細胞介素-13 (IL-13)受體的一個亞基。該基因在包括惡性膠質瘤在內的多種人類腫瘤中均有高表達。檢測45例間變性星形細胞瘤(AAs)、間變性星形細胞瘤(GBMs)、間變性星形細胞瘤(GBMs)組織中IL-13Ralpha2的表達水平。半定量逆轉錄實時聚合酶鏈反應(PCR)檢測IL-13Ralpha2表達，ABI PRISM 7700和Qiagen定量SYBR Green PCR試劑盒檢測。IL-13Ralpha2的表達水平(15倍)在frGBMs中較初級GBMs降低(p = 0.014)，在全部未經(jīng)治療的惡性星形細胞瘤(AAs和GBMs)中較經(jīng)治療的惡性星形細胞瘤(frGBMs)降低15倍以上(p = 0.003)。與GBMs相比，frGBMs中IL-13Ralpha2的表達似乎更低。IL-13細胞毒素的抗腫瘤作用在frGBM中可能大大降低，或者只有在細胞毒素含量較高的情況下才能達到，因為細胞毒素的靶結構表達明顯降低。

　　該論文主要研究人員之一為INC國際神經(jīng)外科醫(yī)生集團旗下組織國際神經(jīng)外科顧問團(WANG)成員，德國漢諾威國際神經(jīng)科學研究所(INI)神經(jīng)外科教授和血管神經(jīng)外科主任巴特朗菲教授。巴特朗菲教授擅長大腦半球病變、腦干病變、腦血管疾病、腦內深層區(qū)膠質瘤、顱頸交界處的病變等的腫瘤切除術、神經(jīng)吻合術以及各種椎管內腫瘤切除術，以高超的技術手法和順利前提下高切除率手術而，在中國患者群中被尊稱為“巴教授”。每年的手術量在400臺以上，且是高難度手術。

　　巴特朗菲教授作為INC國際神經(jīng)外科醫(yī)生集團旗下組織國際神經(jīng)外科顧問團(WANG)中的一員，曾受邀來華參與了多場國內高要求的神經(jīng)外科學術會議，與國內眾多神經(jīng)外科專家共同聚首探討當前前沿的神經(jīng)外科咨詢理念、方法和技術，促進了中外神經(jīng)外科事業(yè)的交流與發(fā)展。

• 文章標題：白介素-13受體IL-13Ralpha2在治療復發(fā)性惡性膠質瘤中的表達降低
• 更新時間：2025-02-13 14:08:41